Canaccord analyst Elyse Shapiro downgraded Mayne Pharma to Hold from Buy with a price target of A$3.80, down from A$7.40. The analyst sees a lot for new management to work through after the company divested its retail generics portfolio.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on MAYNF: